Reikes Peter N 4

What Happened

• Peter N. Reikes, a director of Ionis Pharmaceuticals (IONS), received a grant of stock options covering 10,753 shares on 2026-06-04. The Form 4 lists the acquisition price as $0.00 (derivative award, transaction code "A"); no cash was paid on grant and the filing shows $0 total value for the transaction.
• The option award was issued under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan and was exercisable as to 0 shares on the grant date.

Key Details

• Transaction date: 2026-06-04; Report filed: 2026-06-08 (filed within the SEC two-business-day window).
• Transaction type: Award/Grant of stock options (derivative), 10,753 option shares; price reported $0.00 on Form 4. Exercise/strike price is not stated in the filing.
• Vesting: Vests in three equal annual installments; first vesting on 06/04/2027, fully vested on 06/04/2029 (per footnote F1).
• Shares owned following the transaction: Not specified in the Form 4.
• No 10b5-1 plan, tax-withholding sale, or late-filing indication is noted in this filing.

Context

• This is a director compensation grant, not an open-market purchase or immediate sale. Because the options are not exercisable on grant and vest over three years, this is a future upside opportunity for the director rather than an immediate change in stock ownership.
• Grants to non-employee directors are common and typically reflect compensation rather than a direct bullish or bearish insider signal.